L0521

Lipoxin A₄

ethanol solution

• Synonym(e): (5S,6R,15S)-Trihydroxy-(7E,9E,11Z,13E)-Eicosatetraenoic acid
• Empirische Formel (Hill-System): C₂₀H₃₂O₅
• CAS-Nummer: 89663-86-5
• Molekulargewicht: 352.47
• EG-Nummer: 200-578-6
• MDL-Nummer: MFCD00065845
• UNSPSC-Code: 12352211
• PubChem Substanz-ID: 24896257
• NACRES: NA.77

Eigenschaften

• Form: ethanol solution
• Qualitätsniveau: 200
• Versandbedingung: dry ice
• Lagertemp.: −20°C
• SMILES String: CCCCC[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC(O)=O
• InChI: 1S/C20H32O5/c1-2-3-8-12-17(21)13-9-6-4-5-7-10-14-18(22)19(23)15-11-16-20(24)25/h4-7,9-10,13-14,17-19,21-23H,2-3,8,11-12,15-16H2,1H3,(H,24,25)/b6-4-,7-5+,13-9+,14-10+/t17-,18+,19-/m0/s1
• InChIKey: IXAQOQZEOGMIQS-SSQFXEBMSA-N

Beschreibung

Biochem./physiol. Wirkung

Lipoxin A4 (LXA4) is synthesized from arachidonic acid and is an endogenous lipoxygenase-derived eicosanoid mediator. It is a potent human protein kinase C activator. It inhibits cytotoxicity of natural killer cells. LXA4 regulates the immune system and inflammation. In the brain, it modulates neuronal signaling and slow wave sleep. LXA4 binds to cannabinoid receptors. LXA4 plays a key role in the maintenance of endometrium and reproductive function. Depletion of LXA4 contributes to the pathophysiology of cystic fibrosis (CF).

Verpackung

Packaged under argon.

Sicherheitshinweise

• Piktogramme: GHS02,GHS07
• Signalwort: Danger
• H-Sätze: H225,H319
• P-Sätze: P210 - P233 - P240 - P241 - P242 - P305 + P351 + P338
• Gefahreneinstufungen: Eye Irrit. 2 - Flam. Liq. 2
• Lagerklassenschlüssel: 3 - Flammable liquids
• WGK: WGK 2
• Flammpunkt (°F): 55.4 °F
• Flammpunkt (°C): 13 °C
• Persönliche Schutzausrüstung: Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter